下载掌阅APP，畅读海量书库
立即打开
1.ZHANG Z，LI W，PROCISSI，et al.Rapid dramatic alterations to the tumor microstructure in pancreatic cancer following irreversible electroporation ablation.Nanomedicine（Lond），2014，9（8）:1181-1192.
2.RICKE J，JÜRGENS J H，Deschamps F，et al.Irreversible electroporation（IRE）fails to demonstrate efficacy in a prospective multicenter phase Ⅱ trial on lung malignancies:the ALICE trial.Cardiovasc Intervent Radiol，2015，38（2）:401-408.
3.COELEN R J S，VOGEL J A，VROOMEN L，et al.Ablation with irreversible electroporation in patients with advanced perihilar cholangiocarcinoma（ALPACA）:a multicentre phase Ⅰ/Ⅱ feasibility study protocol.#N/A，2017，7（9）:e015810.
4.BEITEL-WHITE N，MARTIN R C G，LI Y，et al.Real-time prediction of patient immune cell modulation during irreversible electroporation therapy.Sci Rep，2019，9（1）:17739.
5.BELFIORE M P，REGINELLI A，MAGGIALETTI N，et al.Preliminary results in unresectable cholangiocarcinoma treated by CT percutaneous irreversible electroporation:feasibility，safety and efficacy.Med Oncol，2020，37（5）:45.
6.DAI J C，MORGAN T N，STEINBERG R L，et al.Irreversible Electroporation for the Treatment of Small Renal Masses:5-Year Outcomes.J Endourol，2021，35（11）:1586-1592.
7.LI J，WANG J，ZHANG X，et al.Cardiac impact of high-frequency irreversible electroporation using an asymmetrical waveform on liver in vivo.BMC Cardiovasc Disord，2021，21（1）:581.
8.LI J，ZHANG X B，WANG J J，et al.Comparison between high-frequency irreversible electroporation and irreversible electroporation ablation of small swine liver:follow-up of DCE-MRI and pathological observations.Chin Med J（Engl），2021，134（17）:2081-2090.
9.NARAYANAN G，BILIMORIA M M，HOSEIN P J，et al.Multicenter randomized controlled trial and registry study to assess the safety and efficacy of the NanoKnife ® system for the ablation of stage 3 pancreatic adenocarcinoma:overview of study protocols.BMC Cancer，2021，21（1）:785.
10.NARAYANAN G，DAYE D，WILSON N M，et al.Ablation in Pancreatic Cancer:Past，Present and Future.Cancers（Basel），2021，13（11）.